Pretargeted Radioimmunotherapy using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma

PURPOSE: Pretargeted radioimmunotherapy (PRIT) using streptavidin (SAv)-biotin technology can deliver higher therapeutic doses of radioactivity to tumors than conventional RIT. However, “endogenous” biotin can interfere with the effectiveness of this approach by blocking binding of radiolabeled biot...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Park, Steven I., Shenoi, Jaideep, Frayo, Shani M., Hamlin, Donald K., Lin, Yukang, Wilbur, D. Scott, Stayton, Patrick S., Orgun, Nural, Hylarides, Mark, Buchegger, Franz, Kenoyer, Aimee L., Axtman, Amanda, Gopal, Ajay K., Green, Damian J., Pagel, John M., Press, Oliver W.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2011
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3229652/
https://ncbi.nlm.nih.gov/pubmed/21976541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-1204
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia